Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-0217/S001 and Pembrolizumab in Advanced Pancreatic Cancer
NCT05916261Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2023
- Primary completion
- Nov 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of mRNA-0217 in pancreatic cancer (PC) (2 arms), sponsored by Ruijin Hospital. Primary endpoints: Maximum Tolerated Dose at 27 weeks, Antigen-specific T cell reaction at 27 weeks and 2 more. Started Apr 2023; status: recruiting.
02
Drugs
mRNA-0217
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05916261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05916261.